J&J earnings set ‘negative tone’; Shkreli vs. the FTC
Source ↗
👁 0
💬 0
A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.
Comments (0)